β-defensin 36 Inhibitors
β-defensin 36 inhibitors are a class of compounds designed to selectively inhibit the activity of β-defensin 36, a member of the β-defensin family of antimicrobial peptides. β-defensins are small, cysteine-rich peptides characterized by their conserved disulfide bridges, which contribute to their structural stability. In the case of β-defensin 36, its function, like other defensins, includes interactions with microbial membranes, where it can exert influence by altering membrane integrity and permeability. Inhibitors targeting β-defensin 36 are designed to modulate or prevent its biological activity by disrupting its interaction with specific molecular targets. These inhibitors may act through a variety of mechanisms, including direct binding to the peptide, allosteric modulation, or interference with its synthesis or post-translational modifications.
The molecular design of β-defensin 36 inhibitors typically involves identifying key structural motifs that are essential for the peptide's biological function. These motifs often include the disulfide bridges, specific hydrophobic regions, and positively charged residues. Researchers focus on small molecules, peptides, or other chemical entities that can either compete with β-defensin 36 for binding sites or destabilize its structure. Inhibition can also be achieved through targeting regulatory pathways responsible for β-defensin 36's expression. This approach requires a deep understanding of its genetic regulation, transcriptional factors, and signaling cascades. Investigating the precise molecular interactions between β-defensin 36 and its inhibitors often involves advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR), and molecular dynamics simulations to elucidate binding affinities and structural conformations.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor disrupting DNA repair. Olaparib indirectly inhibits β-defensin 36 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 36 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 36, as PI3K/AKT signaling is implicated in the regulation of β-defensin 36 transcription by modulating specific transcription factors. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 36 by blocking NFAT activation, a key regulator of β-defensin 36 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 36 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 36 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 36, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 36. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 36 by altering histone acetylation, influencing the accessibility of the β-defensin 36 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $163.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 36, as HIF-1α enhances β-defensin 36 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $166.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 36, as TLR4 activation is known to upregulate β-defensin 36 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 36 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 36 through control of translation initiation. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $430.00 $1389.00 | 1 | |
Notch signaling pathway inhibitor. RO4929097 indirectly suppresses β-defensin 36, as Notch signaling is linked to the regulation of β-defensin 36 expression by modulating specific transcription factors. | ||||||